Showcasing Discovery Research Portfolio in Three Areas

Early in 2020, KRAS G12D inhibitor candidates advance into IND-enabling studies. The portfolio continues to advance and diversify as other preclinical assets in various solid tumors are evaluated.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.